Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2022-10-25 Sale | 2022-10-26 4:41 pm | PhaseBio Pharmaceuticals Inc | PHAS | NEW ENTERPRISE ASSOCIATES 13 LP NEA Partners 13 Limited Partnership NEA 13 GP Ltd SANDELL SCOTT D KERINS PATRICK J BASKETT FOREST 10% Owner | 1,784,109 | $0.147 | $262,264 | 4,857,525 (Direct) | View |
2022-05-23 Sale | 2022-05-24 5:14 pm | PhaseBio Pharmaceuticals Inc | PHAS | Burkhardt Glen SVP of Human Resources | 11,248 | $0.79 | $8,886 | 0 (Direct) | View |
2021-08-18 Purchase(A) | 2022-05-20 4:47 pm | PhaseBio Pharmaceuticals Inc | PHAS | Hutson Nancy J Director | 3,000 | $3.08 | $9,240 | 37,760 (Indirect Direct) | View |
2021-11-19 Sale | 2021-11-23 6:50 pm | PhaseBio Pharmaceuticals Inc | PHAS | Burkhardt Glen VP, Human Resources | 5,766 | $2.37 | $13,665 | 0 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2023-05-19 Option Award | 2023-05-19 4:18 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | van den Broek Richard Director | 3,750 | $0 | 0 (Direct) | View |
2023-05-19 Exercise | 2023-05-19 4:18 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | van den Broek Richard Director | 3,750 | $0 | 0 (Direct) | View |
2023-05-19 Exercise | 2023-05-19 4:18 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Thorp Clay Director | 3,750 | $0 | 3,581,733 (Direct) | View |
2023-05-19 Exercise | 2023-05-19 4:18 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Humphries William D. Director | 2,538 | $0 | 2,538 (Direct) | View |
2023-05-19 Exercise | 2023-05-19 4:17 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | HARRIGAN EDMUND Director | 3,750 | $0 | 9,750 (Direct) | View |
2023-05-19 Exercise | 2023-05-19 4:17 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Sapir Alex Director | 3,750 | $0 | 3,750 (Direct) | View |
2023-05-19 Exercise | 2023-05-19 4:16 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Loewy Caroline M Director | 3,750 | $0 | 3,750 (Direct) | View |
2023-05-19 Exercise | 2023-05-19 4:15 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Hutson Nancy J Director | 3,750 | $0 | 41,510 (Direct) | View |
2022-05-19 Option Award(A) | 2022-06-10 4:20 pm | N/A 2032-05-18 | PhaseBio Pharmaceuticals Inc | PHAS | Humphries William D. Director | 14,380 | $0 | 14,380 (Direct) | View |
2022-05-20 Option Award | 2022-05-24 5:15 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Arnold Susan Elizabeth SVP, Technical Operations | 10,917 | $0.6813 | 41,236 (Direct) | View |
2022-05-20 Option Award | 2022-05-24 5:14 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Mow Jonathan P Chief Executive Officer | 10,918 | $0.6813 | 183,701 (Direct) | View |
2022-05-20 Option Award | 2022-05-24 5:14 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Burkhardt Glen SVP of Human Resources | 11,248 | $0.6813 | 0 (Direct) | View |
2022-05-20 Option Award | 2022-05-24 5:13 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Hanson Kristopher SVP and General Counsel | 4,831 | $0.6813 | 8,463 (Direct) | View |
2022-05-20 Option Award | 2022-05-24 5:13 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Birchall Jonathan Chief Commercial Officer | 20,000 | $0.6813 | 20,000 (Direct) | View |
2022-05-20 Option Award | 2022-05-24 5:12 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Sharp John P Chief Financial Officer | 6,026 | $0.6813 | 65,767 (Direct) | View |
2022-05-19 Option Award | 2022-05-20 4:46 pm | N/A 2032-05-18 | PhaseBio Pharmaceuticals Inc | PHAS | Humphries William D. Director | 21,250 | $0 | 21,250 (Direct) | View |
2022-05-19 Option Award | 2022-05-20 4:46 pm | N/A 2032-05-18 | PhaseBio Pharmaceuticals Inc | PHAS | Thorp Clay Director | 21,250 | $0 | 21,250 (Direct) | View |
2022-05-19 Option Award | 2022-05-20 4:45 pm | N/A 2032-05-18 | PhaseBio Pharmaceuticals Inc | PHAS | Hutson Nancy J Director | 21,250 | $0 | 21,250 (Direct) | View |
2022-05-19 Option Award | 2022-05-20 4:45 pm | N/A 2032-05-18 | PhaseBio Pharmaceuticals Inc | PHAS | Sapir Alex Director | 21,250 | $0 | 21,250 (Direct) | View |
2022-05-19 Option Award | 2022-05-20 4:44 pm | N/A 2032-05-18 | PhaseBio Pharmaceuticals Inc | PHAS | Loewy Caroline M Director | 21,250 | $0 | 21,250 (Direct) | View |
2022-05-19 Option Award | 2022-05-20 4:44 pm | N/A 2032-05-18 | PhaseBio Pharmaceuticals Inc | PHAS | HARRIGAN EDMUND Director | 21,250 | $0 | 21,250 (Direct) | View |
2022-05-19 Option Award | 2022-05-20 4:44 pm | N/A 2032-05-18 | PhaseBio Pharmaceuticals Inc | PHAS | van den Broek Richard Director | 21,250 | $0 | 21,250 (Direct) | View |
2022-02-24 Option Award | 2022-02-28 7:30 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Sharp John P Chief Financial Officer | 140,250 | $0 | 140,250 (Direct) | View |
2022-02-24 Option Award | 2022-02-28 7:27 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Burkhardt Glen VP, Human Resources | 106,250 | $0 | 106,250 (Direct) | View |
2022-02-24 Option Award | 2022-02-28 7:25 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Birchall Jonathan Chief Commercial Officer | 63,750 | $0 | 63,750 (Direct) | View |
2022-02-24 Option Award | 2022-02-28 7:23 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Lee John Sang Chief Medical Officer | 140,250 | $0 | 140,250 (Direct) | View |
2022-02-24 Option Award | 2022-02-28 7:21 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Arnold Susan Elizabeth SVP, Technical Operations | 106,250 | $0 | 106,250 (Direct) | View |
2022-02-24 Option Award | 2022-02-28 7:19 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Hanson Kristopher VP, Head of Legal | 106,250 | $0 | 106,250 (Direct) | View |
2022-02-24 Option Award | 2022-02-28 7:14 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Mow Jonathan P Chief Executive Officer | 467,500 | $0 | 467,500 (Direct) | View |
2021-11-19 Option Award | 2021-11-23 6:55 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Mow Jonathan P Chief Executive Officer | 5,623 | $2.01 | 172,473 (Direct) | View |
2021-11-19 Option Award | 2021-11-23 6:54 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Arnold Susan Elizabeth SVP, Technical Operations | 2,559 | $2.01 | 30,319 (Direct) | View |
2021-11-19 Option Award | 2021-11-23 6:53 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Sharp John P Chief Financial Officer | 2,017 | $2.01 | 59,741 (Direct) | View |
2021-11-19 Option Award | 2021-11-23 6:51 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Hanson Kristopher VP, Head of Legal | 1,545 | $2.01 | 3,632 (Direct) | View |
2021-11-19 Option Award | 2021-11-23 6:50 pm | N/A N/A | PhaseBio Pharmaceuticals Inc | PHAS | Burkhardt Glen VP, Human Resources | 5,766 | $2.01 | 0 (Direct) | View |
2021-11-08 Option Award | 2021-11-09 8:46 pm | N/A 2031-11-08 | PhaseBio Pharmaceuticals Inc | PHAS | Birchall Jonathan Chief Commercial Officer | 250,000 | $3.37 | 250,000 (Direct) | View |
2021-11-05 Exercise | 2021-11-08 6:26 pm | N/A 2029-02-27 | PhaseBio Pharmaceuticals Inc | PHAS | Hutson Nancy J Director | 8,900 | $3.15 | 43,416 (Direct) | View |
2021-11-05 Exercise | 2021-11-08 6:26 pm | N/A 2028-05-03 | PhaseBio Pharmaceuticals Inc | PHAS | Hutson Nancy J Director | 24,860 | $2.26 | 43,416 (Direct) | View |
2021-11-03 Exercise | 2021-11-03 7:30 pm | 2018-10-08 2024-11-04 | PhaseBio Pharmaceuticals Inc | PHAS | Mow Jonathan P Chief Executive Officer | 20,000 | $1.24 | 275,617 (Direct) | View |
2021-11-03 Exercise | 2021-11-03 7:30 pm | 2020-04-11 2026-05-12 | PhaseBio Pharmaceuticals Inc | PHAS | Sharp John P Chief Financial Officer | 7,500 | $1.68 | 148,306 (Direct) | View |